Gender‐based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient‐level pooled data of six randomized controlled trials
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: To determine the impact of gender on glycaemic control and hypoglycaemia in insulin‐naïve patients with type 2 diabetes ( T2DM ). Methods: Data were pooled from six randomized clinical trials of insulin glargine or NPH insulin in insulin‐naïve, inadequately controlled patients. Female [n = 1251; mean glycated haemoglobin ( HbA1c ) level 8.99%, age 56.91 years, diabetes duration 9.84 years] and male patients (n = 1349; mean HbA1c 8.9%, age 57.47 years, diabetes duration 10.13 years) were started on and treated with insulin glargine or NPH insulin for 24–36 weeks. HbA1c and fasting blood glucose levels, percent achieving HbA1c target of <7% and insulin dose change were recorded. Results: For both men and women, HbA1c levels were significantly reduced over time (p < 0.001); a significantly greater HbA1c reduction was observed in men than in women (−1.36 vs. −1.22; p = 0.002). Significantly fewer women achieved target HbA1c of <7% (p < 0.001). At the study end, women had a significantly higher insulin dose/kg than men (0.47 vs. 0.42 U/kg; p < 0.001). The incidence rates of severe and severe nocturnal hypoglycaemia were significantly higher in women (3.28% vs. 1.85%; p < 0.05 and 2.24% vs. 0.59%; p < 0.001, respectively). Women were more likely to experience severe hypoglycaemia [odds ratio ( OR ) 1.80; 95% confidence interval ( CI ) 1.08, 3.00; p = 0.02] and severe nocturnal hypoglycaemia ( OR : 3.80; 95% CI 1.72, 8.42; p = 0.001). Conclusions: These observations confirm studies that found a smaller improvement in HbA1c and greater hypoglycaemia in women during insulin treatment. Physicians should be aware of the need to determine and closely monitor dosing, particularly in women, to optimize the balance between glycaemic control and hypoglycaemia risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts
The DECODE Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.1.61 · Cited by 608
Increased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434 · cited 1×
“[14] 36 weeks LANMET/6001 Study NPH (n= 49) Pre-study: Sulphonylurea+metformin or metformin alone Δ in HbA1c from baseline to study end”
MethodMiller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429 · cited 2×
“Previous research has established that women are more inclined to experience hypoglycaemia during insulin treatment [8,16]; but the impact of gender on glycaemic control, specifically HbA1c level, is less clear.”
BackgroundPrevalences of Diabetes and Impaired Glucose Regulation in a Danish Population
Glümer, C., Jørgensen, T., & Borch-Johnsen, K. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2335 · Cited by 279
Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219
Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500320 · Cited by 199 · cited 1×
“Continuous glucose monitoring systems in women may represent an important advancement in the management of both glycaemic control and hypoglycaemia, as use of these devices has improved control and safety [28].”
Background
Cited by
Sex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Sex differences in type 2 diabetes
Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05891-x · Cited by 624
Self-citationSex differences underlying pancreatic islet biology and its dysfunction
Gannon, M., Kulkarni, R. N., Tse, H. M., & Mauvais-Jarvis, F. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.017 · Cited by 133
Onishi, Y., Oura, T., Matsui, A., Matsuura, J., & Iwamoto, N. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0552 · Cited by 47
Amuta, A. O., Jacobs, W., Barry, A. E., Popoola, O. A., & Crosslin, K. (2016) · American Journal of Health Education · doi:10.1080/19325037.2016.1203836 · Cited by 22
Melaku, T., Chelkeba, L., Mekonnen, Z., & Kumela, K. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s266105 · Cited by 4
Metadata
- Authors
- Kautzky‐Willer, A., Kosi, L., Lin, J., & Mihaljevic, R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-03-20
- Volume
- 17
- Issue
- 6
- Pages
- 533-540
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2126838326
- Cited by
- 112
- References
- 11
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.